Ultragenyx Pharmaceutical (RARE) Earnings Analysis
Ultragenyx Pharmaceutical (RARE) has no confirmed upcoming earnings date. Last quarter (2026-02-12) it missed with EPS -1.29 USD vs -1.2 USD est (-7.5%). It has beaten estimates in 1/3 recent quarters (33%). Trailing P/E -4.52.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does RARE next report earnings?
No confirmed upcoming earnings date is currently scheduled for RARE. This page updates as the calendar is published.
RARE earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-12 | -1.29 USD | -1.2 USD | -7.5% | Miss |
| 2025-02-13 | -1.39 USD | -1.32 USD | -5.3% | Miss |
| 2024-08-01 | -1.52 USD | -1.64 USD | +7.3% | Beat |
Beat rate: 1/3 (33%) over reported quarters with consensus data.
RARE valuation and analyst view
| Trailing P/E | -4.52 |
|---|---|
| Trailing EPS | -6.0573 USD |
| Price / book | -11.78 |
| Dividend yield | 0.00% |
| Market cap | 2.71B |
| Analyst consensus | Buy (26 buy / 6 hold / 1 sell) |
| Avg price target | 36.4 USD |
Related research pages
Frequently asked questions
When is Ultragenyx Pharmaceutical (RARE)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for RARE. This page updates as the calendar is published.
Did RARE beat earnings last quarter?
In its 2026-02-12 report, RARE posted EPS of -1.29 USD versus a -1.2 USD estimate — a miss of 7.5%.
What is RARE's earnings track record?
Over the last 3 reported quarters with consensus data, RARE beat estimates 1 times (33%).
What is RARE's current P/E ratio and EPS?
RARE trades at a trailing P/E of -4.52 on trailing EPS of -6.057296222664016 USD.
What do analysts rate RARE?
Analyst consensus is "Buy" across 33 ratings (0 strong buy, 26 buy, 6 hold, 1 sell, 0 strong sell). Average 12-month price target: 36.4 USD.